NeoGenomics (NASDAQ:NEO) and Rennova Health (OTCMKTS:RNVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Risk & Volatility
NeoGenomics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Rennova Health has a beta of -2.21, indicating that its stock price is 321% less volatile than the S&P 500.
Institutional and Insider Ownership
80.8% of NeoGenomics shares are held by institutional investors. 12.2% of NeoGenomics shares are held by company insiders. Comparatively, 20.2% of Rennova Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of current ratings and target prices for NeoGenomics and Rennova Health, as reported by MarketBeat.com.
||Strong Buy Ratings
NeoGenomics presently has a consensus target price of $19.91, indicating a potential upside of 10.79%. Given NeoGenomics’ higher possible upside, equities research analysts plainly believe NeoGenomics is more favorable than Rennova Health.
This table compares NeoGenomics and Rennova Health’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings & Valuation
This table compares NeoGenomics and Rennova Health’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
NeoGenomics has higher revenue and earnings than Rennova Health.
NeoGenomics beats Rennova Health on 10 of the 11 factors compared between the two stocks.
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
About Rennova Health
Rennova Health, Inc., together with its subsidiaries, provides a suite of healthcare related products and services to healthcare providers in the United States. The company operates in three segments: Laboratory Services, Supportive Software Solutions, and Decision Support and Informatics Operations. It provides toxicology, clinical pharmacogenetics, and esoteric testing services. The company also offers Advantage, a HIPAA compliant software; Clinlab, a Windows-based Web-enabled laboratory information management system; and Medical Mime, a suite of solutions, which include an optimized Electronic health records (EHR) for substance abuse and behavioral health providers, a dictation-based ambulatory EHR for physician practices, and advanced transcription services. In addition, it develops and markets interpretation and decision support solutions that enhance cancer diagnoses and treatment through actionable data analytics and reporting for oncologists and their patients. Rennova Health, Inc. was founded in 2005 and is headquartered in West Palm Beach, Florida.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.